Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Brilliance Bio-tech is a Chinese biotechnology company specializing in the development of regenerative medicine products and advanced biomaterials. The company utilizes a proprietary extracellular matrix (ECM) technology platform derived from porcine small intestinal submucosa (SIS) to develop non-crosslinked biological materials that facilitate natural tissue repair. Their product portfolio includes surgical meshes for hernia repair, anal fistula plugs, dental membranes, and wound dressings, many of which have received NMPA and FDA clearances. By providing scaffolds that promote endogenous tissue regeneration, Brilliance Bio-tech addresses critical clinical needs in general surgery, stomatology, and wound management. The company is headquartered in Beijing and maintains integrated research, development, and manufacturing capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Brilliance Bio-tech.